What You Should Know:
- Eli Lilly and Company announced positive topline Phase 3 results from ACHIEVE-1, a study evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes whose blood sugar was inadequately controlled through diet and exercise alone.
- Orforglipron stands out as the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3
Read More
GLP-1
Phenomix Sciences Launches Clinical Trial to Predict GLP-1 Response Using Precision Obesity Test
What You Should Know:
- Phenomix Sciences (Phenomix), a commercial precision obesity medicine biotechnology company, today announced the initiation of its first prospective, placebo-controlled clinical study.
- The research will evaluate the MyPhenome™ test's ability to predict individual patient responses to semaglutide, a GLP-1-based therapy that has become a cornerstone in the treatment of obesity.
First Prospective Clinical Study of Semaglutide Using MyPhenome™
Read More
Virta Health Cuts GLP-1 Use for Weight Loss Over 50%, Driving Cost Savings for Payers
What You Should Know:
- Virta Health, a leader in diabetes reversal and sustainable weight loss through its nutrition-first methodology, has announced early results from its recently launched Sustainable Weight Loss GLP-1 prescribing capabilities.
- These outcomes signal a potentially transformative shift in obesity and weight loss management, offering organizations a responsible framework for covering GLP-1 medications while actively reducing reliance and controlling overall
Read More
Collective Health, Noom Health Offer Integrated GLP-1 Weight Management Solution
What You Should Know:
- Collective Health, a leader in employee health benefits, and Noom Health, the enterprise division of digital healthcare leader Noom announced a partnership to deliver Collective Health + Noom Med with SmartRx.
- The new program provides employers with an integrated weight management solution that includes a GLP-1 drug program, addressing the growing need for effective and affordable weight loss strategies.
Addressing the Obesity Epidemic
With
Read More
Affirm + FuturHealth Partner to Make GLP-1 Medications More Accessible with Flexible Payment Options
What You Should Know:
- FuturHealth, a provider of personalized weight-loss solutions partners with Affirm, the payment network that empowers consumers and helps merchants drive growth.
- The collaboration will enable FuturHealth customers to use Affirm's flexible, transparent pay-over-time options to purchase medications and wellness solutions.
Flexible, Transparent Way to Pay Over Time for GLP-1 Medications and Wellness Solutions
Now, FuturHealth customers who are
Read More
Quantum Health Launches New GLP-1 Solution for Employers
What You Should Know:
- Quantum Health, a provider of healthcare navigation and care coordination, has announced the expansion of its Premier Pharmacy platform to offer self-insured employers a new GLP-1 weight management solution.
- The GLP-1 offering, powered by Vida Health, aims to optimize prescribing patterns, improve clinical outcomes, and provide comprehensive member support for weight loss.
Growing Demand for GLP-1 Medications
The need for effective weight
Read More
PatchMD Introduces New GLP-1 Support Patches for Individuals on Weight Loss Medications
What You Should Know:
- PatchMD, a pioneer in transdermal nutrient delivery, has unveiled its new GLP-1 Support Patch Collection, designed to provide essential support for individuals using GLP-1 receptor agonist medications such as Ozempic, Wegovy, and Mounjaro for weight management.
- GLP-1 receptor agonists have revolutionized medical weight loss, but they often come with side effects like nausea and appetite suppression, and can lead to nutrient deficiencies.
Why
Read More
Teladoc Health, Eli Lilly Partner to Add GLP-1 Self-Pay Option to Comprehensive Weight Care
What You Should Know:
- Teladoc Health, the global leader in virtual care announced a partnership with Gifthealth, a digital pharmacy platform and partner of Eli Lilly's LillyDirect program, to improve access to Zepbound® (tirzepatide) for weight management.
- The collaboration will enable eligible Teladoc Health members enrolled in the Comprehensive Weight Care Program to receive convenient and affordable access to this FDA-approved medication.
Streamline Access to Tirzepatide
Read More
Wondr Health Expands Weight Loss Program with Support for GLP-1 Users
What You Should Know:
- Wondr Health, a leader in virtual metabolic health programs, has announced the expansion of its weight and obesity care solution, Wondr Plus.
- The enhancement provides comprehensive lifestyle support and nutrition counseling for employees using GLP-1 weight-loss medications, addressing the challenges of medication adherence and side effects.
Addressing the Need for GLP-1 Support
While GLP-1 medications have shown promising results for weight loss,
Read More
Bariatric Surgeries Decline as GLP-1s Use Rises, Impacting Hospital Margins
What You Should Know:
- A new report from Strata Decision Technology reveals a significant decline in the number of bariatric surgeries performed in U.S. hospitals in recent years.
- The trend coincides with the rising popularity of weight-loss medications like semaglutide (GLP-1s), which have gained widespread adoption since their approval for chronic weight management.
Declining Surgical Volumes
Strata's analysis of data from 809 hospitals nationwide shows a clear
Read More
